Last reviewed · How we verify
bepotastine besilate ophthalmic solution — Competitive Intelligence Brief
marketed
H1-receptor, mast cells
Small molecule
Live · refreshed every 30 min
Target snapshot
bepotastine besilate ophthalmic solution (bepotastine besilate ophthalmic solution) — Bausch & Lomb Incorporated. Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| bepotastine besilate ophthalmic solution TARGET | bepotastine besilate ophthalmic solution | Bausch & Lomb Incorporated | marketed | H1-receptor, mast cells | ||
| Bepreve | BEPOTASTINE | Bausch Health | marketed | Histamine-1 Receptor Antagonist | H1-receptor, mast cells | 2009-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- bepotastine besilate ophthalmic solution CI watch — RSS
- bepotastine besilate ophthalmic solution CI watch — Atom
- bepotastine besilate ophthalmic solution CI watch — JSON
- bepotastine besilate ophthalmic solution alone — RSS
Cite this brief
Drug Landscape (2026). bepotastine besilate ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/bepotastine-besilate-ophthalmic-solution. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab